Pupillometry might sound like a technique a teacher would use to keep her class under control, but it’s actually an ingenious way of assessing brain health by measuring data from patients’ eyes.
A donor-derived cell-free DNA assay from Natera Inc. detected allograft rejection earlier and more precisely than other currently available tests for patients who have undergone kidney transplant, regardless of donor-recipient relationships, according to published study results.
Natera plans to focus on three main goals in the coming year, according to its new CEO, Steve Chapman: expanding its leadership in reproductive health by pushing toward becoming cash-flow break-even in that business, establishing Signatera as a standard test in cancer care, and commercializing and securing reimbursement coverage for its kidney transplantation test.
Natera Inc. recently announced the assignment of a unique Z code for the company’s kidney transplant rejection assay in preparation for the commercialization of its upcoming 2019 Clinical Laboratory Improvement Amendments-certified lab developed test.
Sterility assurance device developer Verrix said today that it raised $8 million in a Series B round of financing, lifting the total the company has raised so far to $17.5 million.
Stryker has closed its US$1.4 billion acquisition of K2M. With the acquisition, K2M will become a wholly owned subsidiary of Stryker, the companies said.
Stryker paid US$27.50 per share for each outstanding share of K2M, representing a 27% premium over K2M’s average closing price during the 90 days of trading ended 29 August.
A comparison of interbody cages has resulted in the publication of new results on Allendale, New Jersey-based Stryker Spine’s 3D-printed Tritanium cages.
The pre-clinical animal study, “Bony Ingrowth Potential of 3D Printed Porous Titanium Alloy: A Direct Comparison of Interbody Cage Materials in an In Vivo Ovine Lumbar Fusion Model,” was published in the July issue of The Spine Journal.”